A total of @ patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy were randomly assigned ( in a @:@ ratio ) to receive @ mg of nivolumab per kilogram of body weight intravenously every @ weeks or a @-mg everolimus tablet orally once daily .